CN119137117A - 蛋白酪氨酸磷酸酶抑制剂及其用途 - Google Patents

蛋白酪氨酸磷酸酶抑制剂及其用途 Download PDF

Info

Publication number
CN119137117A
CN119137117A CN202380032050.5A CN202380032050A CN119137117A CN 119137117 A CN119137117 A CN 119137117A CN 202380032050 A CN202380032050 A CN 202380032050A CN 119137117 A CN119137117 A CN 119137117A
Authority
CN
China
Prior art keywords
alkyl
heterocycloalkyl
cycloalkyl
heteroaryl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380032050.5A
Other languages
English (en)
Chinese (zh)
Inventor
杰森·罗兰
瑟吉欧·G·都荣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nerio Medical Co
Original Assignee
Nerio Medical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerio Medical Co filed Critical Nerio Medical Co
Publication of CN119137117A publication Critical patent/CN119137117A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN202380032050.5A 2022-02-02 2023-02-01 蛋白酪氨酸磷酸酶抑制剂及其用途 Pending CN119137117A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263305786P 2022-02-02 2022-02-02
US63/305,786 2022-02-02
PCT/US2023/061727 WO2023150535A1 (en) 2022-02-02 2023-02-01 Protein tyrosine phosphatase inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
CN119137117A true CN119137117A (zh) 2024-12-13

Family

ID=87552989

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380032050.5A Pending CN119137117A (zh) 2022-02-02 2023-02-01 蛋白酪氨酸磷酸酶抑制剂及其用途

Country Status (7)

Country Link
US (1) US20250136564A1 (cg-RX-API-DMAC7.html)
EP (1) EP4472976A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025507292A (cg-RX-API-DMAC7.html)
CN (1) CN119137117A (cg-RX-API-DMAC7.html)
AR (1) AR128418A1 (cg-RX-API-DMAC7.html)
TW (1) TW202337459A (cg-RX-API-DMAC7.html)
WO (1) WO2023150535A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL314650A (en) * 2022-02-02 2024-09-01 Nerio Therapeutics Inc Protein tyrosine phosphatase inhibitors and uses thereof
WO2024243441A1 (en) 2023-05-24 2024-11-28 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
WO2025030008A1 (en) * 2023-08-02 2025-02-06 Nerio Therapeutics, Inc. Protein tyrosine phosphatase inhibitor combinations
CN120004876B (zh) * 2023-11-16 2026-02-06 英矽智能科技(上海)有限公司 蛋白酪氨酸磷酸酶抑制剂及其应用
CN117343052B (zh) * 2023-12-04 2024-02-06 英矽智能科技(上海)有限公司 蛋白酪氨酸磷酸酶抑制剂及其应用
WO2026108900A1 (zh) * 2024-11-20 2026-05-28 湖北生物医药产业技术研究院有限公司 作为蛋白质酪氨酸磷酸酶抑制剂的含苯并环类化合物及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA94724C2 (en) * 2005-12-08 2011-06-10 Новартис Аг Thiadiazolidinone derivatives as antidiabetic agents
UA94921C2 (en) * 2005-12-08 2011-06-25 Новартис Аг 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
JP2016516004A (ja) * 2013-02-22 2016-06-02 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 抗糖尿病二環式化合物
KR102983496B1 (ko) * 2019-03-14 2026-06-29 칼리코 라이프 사이언시스 엘엘씨 단백질 티로신 포스파타제 억제제 및 이의 사용 방법
EP4211122A1 (en) * 2020-09-11 2023-07-19 Calico Life Sciences LLC Protein tyrosine phosphatase inhibitors and methods of use thereof
EP4305030A4 (en) * 2021-03-11 2025-05-21 Kumquat Biosciences Inc. HETEROCYCLES AND THEIR USES

Also Published As

Publication number Publication date
TW202337459A (zh) 2023-10-01
EP4472976A1 (en) 2024-12-11
EP4472976A4 (en) 2026-03-25
JP2025507292A (ja) 2025-03-18
WO2023150535A1 (en) 2023-08-10
AR128418A1 (es) 2024-05-08
US20250136564A1 (en) 2025-05-01

Similar Documents

Publication Publication Date Title
CN119365452A (zh) 蛋白酪氨酸磷酸酶抑制剂及其用途
RU2692766C1 (ru) Пролекарства пиридонамидов, применяемые в качестве модуляторов натриевых каналов
JP2025505994A (ja) プロテインチロシンホスファターゼ阻害剤およびその使用
JP2025507292A (ja) プロテインチロシンホスファターゼ阻害剤およびその使用
US20250145624A1 (en) Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereof
TW201144310A (en) [5,6] heterocyclic compound
CN118922412A (zh) 蛋白酪氨酸磷酸酶抑制剂及其用途
CN119053592A (zh) 吡唑膜相关的酪氨酸和苏氨酸特异性cdc2抑制激酶(pkmyt1)抑制剂及其用途
CN119053601A (zh) 泛素特异性蛋白酶1(usp1)的小分子抑制剂及其用途
WO2023155870A1 (en) Membrane-associated tyrosine-and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereof
EP4594305A1 (en) Tead inhibitors and methods of uses thereof
CN119630662A (zh) Cbl-b抑制剂及其应用方法
CN118974027A (zh) 蛋白质酪氨酸磷酸酶抑制剂及其用途
CN118871439A (zh) 外核苷酸焦磷酸酶-磷酸二酯酶(enpp1)抑制剂及其用途
CN118829642A (zh) 二酰基甘油激酶(DGK)α抑制剂及其用途
CN121620514A (zh) 蛋白质酪氨酸磷酸酶降解剂及其用途
CN121646467A (zh) 蛋白质酪氨酸磷酸酶抑制剂的组合
CN121443601A (zh) 作为cdk2/4/6抑制剂的取代的噻唑化合物及其使用方法
WO2024153147A1 (zh) 一种氮杂环烷烃化合物、药物组合物及其用途
HK40116343A (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof
WO2025201397A1 (en) Tead inhibitors and methods of uses thereof
CN121712774A (zh) 靶向pkmyt1的双官能化合物和使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination